The NTD-CTD intersubunit interface plays a critical role in assembly and stabilization of the HIV-1 capsid

Retrovirology

Volumn 10, Issue 1, 2013, Pages

  Yufenyuy, Ernest L ^a   Aiken, Christopher ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Assembly; Capsid; Core; Crosslinking; HIV 1; Interface; Reverse transcription; Stability; Uncoating

Indexed keywords

CAPSID PROTEIN;

AMINO ACID SUBSTITUTION; AMINO TERMINAL DOMAIN CARBOXY TERMINAL DOMAIN INTERSUBUNIT INTERFACE; ARTICLE; CONTROLLED STUDY; DISULFIDE BOND; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR STABILITY; NONHUMAN; POINT MUTATION; PROTEIN CROSS LINKING; PROTEIN STRUCTURE; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION; TRANSMISSION ELECTRON MICROSCOPY; VIRION; VIRUS ASSEMBLY; VIRUS CAPSID; VIRUS MUTANT; VIRUS PARTICLE; VIRUS REPLICATION; WILD TYPE;

CELL LINE; DNA MUTATIONAL ANALYSIS; HIV CORE PROTEIN P24; HIV-1; HUMANS; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN INTERACTION DOMAINS AND MOTIFS; VIRUS ASSEMBLY;

HUMAN IMMUNODEFICIENCY VIRUS 1; MIRIDAE;

EID: 84874539069     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-10-29     Document Type: Article

References (58)

1. Ganser BK, Li S, Klishko VY, Finch JT, Sundquist WI. Assembly and analysis of conical models for the HIV-1 core. Science 1999, 283:80-83. 10.1126/science.283.5398.80, 9872746.
2. Ganser-Pornillos BK, Yeager M, Sundquist WI. The structural biology of HIV assembly. Curr Opin Struct Biol 2008, 18:203-217. 10.1016/j.sbi.2008.02.001, 2819415, 18406133.
3. Gamble TR, Yoo S, Vajdos FF, von Schwedler UK, Worthylake DK, Wang H, McCutcheon JP, Sundquist WI, Hill CP. Structure of the carboxyl-terminal dimerization domain of the HIV-1 capsid protein. Science 1997, 278:849-853. 10.1126/science.278.5339.849, 9346481.
4. Gitti RK, Lee BM, Walker J, Summers MF, Yoo S, Sundquist WI. Structure of the amino-terminal core domain of the HIV-1 capsid protein. Science 1996, 273:231-235. 10.1126/science.273.5272.231, 8662505.
5. Byeon IJ, Meng X, Jung J, Zhao G, Yang R, Ahn J, Shi J, Concel J, Aiken C, Zhang P, Gronenborn AM. Structural convergence between Cryo-EM and NMR reveals intersubunit interactions critical for HIV-1 capsid function. Cell 2009, 139:780-790. 10.1016/j.cell.2009.10.010, 2782912, 19914170.
6. Ganser-Pornillos BK, Cheng A, Yeager M. Structure of full-length HIV-1 CA: a model for the mature capsid lattice. Cell 2007, 131:70-79. 10.1016/j.cell.2007.08.018, 17923088.
7. Pornillos O, Ganser-Pornillos BK, Yeager M. Atomic-level modelling of the HIV capsid. Nature 2011, 469:424-427. 10.1038/nature09640, 3075868, 21248851.
8. Pornillos O, Ganser-Pornillos BK, Kelly BN, Hua Y, Whitby FG, Stout CD, Sundquist WI, Hill CP, Yeager M. X-ray structures of the hexameric building block of the HIV capsid. Cell 2009, 137:1282-1292. 10.1016/j.cell.2009.04.063, 2840706, 19523676.
9. Worthylake DK, Wang H, Yoo S, Sundquist WI, Hill CP. Structures of the HIV-1 capsid protein dimerization domain at 2.6 A resolution. Acta Crystallogr D: Biol Crystallogr 1999, 55:85-92.
10. Forshey BM, von Schwedler U, Sundquist WI, Aiken C. Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. J Virol 2002, 76:5667-5677. 10.1128/JVI.76.11.5667-5677.2002, 137032, 11991995.
11. Yang R, Aiken C. A mutation in alpha helix 3 of CA renders human immunodeficiency virus type 1 cyclosporin A resistant and dependent: rescue by a second-site substitution in a distal region of CA. J Virol 2007, 81:3749-3756. 10.1128/JVI.02634-06, 1866112, 17267487.
12. Wacharapornin P, Lauhakirti D, Auewarakul P. The effect of capsid mutations on HIV-1 uncoating. Virology 2007, 358:48-54. 10.1016/j.virol.2006.08.031, 16996553.
13. Hulme AE, Perez O, Hope TJ. Complementary assays reveal a relationship between HIV-1 uncoating and reverse transcription. Proc Natl Acad Sci U S A 2011, 108:9975-9980. 10.1073/pnas.1014522108, 3116424, 21628558.
14. Yang R, Shi J, Byeon IJ, Ahn J, Sheehan JH, Meiler J, Gronenborn AM, Aiken C. Second-site suppressors of HIV-1 capsid mutations: restoration of intracellular activities without correction of intrinsic capsid stability defects. Retrovirology 2012, 9:30. 10.1186/1742-4690-9-30, 3351742, 22515365.
15. Sayah DM, Sokolskaja E, Berthoux L, Luban J. Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature 2004, 430:569-573. 10.1038/nature02777, 15243629.
16. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 2004, 427:848-853. 10.1038/nature02343, 14985764.
17. Stremlau M, Perron M, Lee M, Li Y, Song B, Javanbakht H, Diaz-Griffero F, Anderson DJ, Sundquist WI, Sodroski J. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc Natl Acad Sci U S A 2006, 103:5514-5519. 10.1073/pnas.0509996103, 1459386, 16540544.
18. Jiang J, Ablan SD, Derebail S, Hercik K, Soheilian F, Thomas JA, Tang S, Hewlett I, Nagashima K, Gorelick RJ. The interdomain linker region of HIV-1 capsid protein is a critical determinant of proper core assembly and stability. Virology 2011, 421:253-265. 10.1016/j.virol.2011.09.012, 3573886, 22036671.
19. Noviello CM, Lopez CS, Kukull B, McNett H, Still A, Eccles J, Sloan R, Barklis E. Second-site compensatory mutations of HIV-1 capsid mutations. J Virol 2011, 85:4730-4738. 10.1128/JVI.00099-11, 3126181, 21367891.
20. von Schwedler UK, Stray KM, Garrus JE, Sundquist WI. Functional surfaces of the human immunodeficiency virus type 1 capsid protein. J Virol 2003, 77:5439-5450. 10.1128/JVI.77.9.5439-5450.2003, 153941, 12692245.
21. Dorfman T, Bukovsky A, Ohagen A, Hoglund S, Gottlinger HG. Functional domains of the capsid protein of human immunodeficiency virus type 1. J Virol 1994, 68:8180-8187. 237283, 7966609.
22. von Schwedler UK, Stemmler TL, Klishko VY, Li S, Albertine KH, Davis DR, Sundquist WI. Proteolytic refolding of the HIV-1 capsid protein amino-terminus facilitates viral core assembly. EMBO J 1998, 17:1555-1568. 10.1093/emboj/17.6.1555, 1170503, 9501077.
23. Grigorov B, Decimo D, Smagulova F, Pechoux C, Mougel M, Muriaux D, Darlix JL. Intracellular HIV-1 Gag localization is impaired by mutations in the nucleocapsid zinc fingers. Retrovirology 2007, 4:54. 10.1186/1742-4690-4-54, 1976323, 17683545.
24. Lanman J, Sexton J, Sakalian M, Prevelige PE. Kinetic analysis of the role of intersubunit interactions in human immunodeficiency virus type 1 capsid protein assembly in vitro. J Virol 2002, 76:6900-6908. 10.1128/JVI.76.14.6900-6908.2002, 136311, 12072491.
25. Lanman J, Lam TT, Barnes S, Sakalian M, Emmett MR, Marshall AG, Prevelige PE. Identification of novel interactions in HIV-1 capsid protein assembly by high-resolution mass spectrometry. J Mol Biol 2003, 325:759-772. 10.1016/S0022-2836(02)01245-7, 12507478.
26. Bowzard JB, Wills JW, Craven RC. Second-site suppressors of Rous sarcoma virus Ca mutations: evidence for interdomain interactions. J Virol 2001, 75:6850-6856. 10.1128/JVI.75.15.6850-6856.2001, 114412, 11435564.
27. Cardone G, Purdy JG, Cheng N, Craven RC, Steven AC. Visualization of a missing link in retrovirus capsid assembly. Nature 2009, 457:694-698. 10.1038/nature07724, 2721793, 19194444.
28. Inagaki N, Takeuchi H, Yokoyama M, Sato H, Ryo A, Yamamoto H, Kawada M, Matano T. A structural constraint for functional interaction between N-terminal and C-terminal domains in simian immunodeficiency virus capsid proteins. Retrovirology 2010, 7:90. 10.1186/1742-4690-7-90, 2964592, 20955553.
29. Berthet-Colominas C, Monaco S, Novelli A, Sibai G, Mallet F, Cusack S. Head-to-tail dimers and interdomain flexibility revealed by the crystal structure of HIV-1 capsid protein (p24) complexed with a monoclonal antibody Fab. EMBO J 1999, 18:1124-1136. 10.1093/emboj/18.5.1124, 1171204, 10064580.
30. Khorasanizadeh S, Campos-Olivas R, Summers MF. Solution structure of the capsid protein from the human T-cell leukemia virus type-I. J Mol Biol 1999, 291:491-505. 10.1006/jmbi.1999.2986, 10438634.
31. Momany C, Kovari LC, Prongay AJ, Keller W, Gitti RK, Lee BM, Gorbalenya AE, Tong L, McClure J, Ehrlich LS. Crystal structure of dimeric HIV-1 capsid protein. Nat Struct Biol 1996, 3:763-770. 10.1038/nsb0996-763, 8784350.
32. Kingston RL, Fitzon-Ostendorp T, Eisenmesser EZ, Schatz GW, Vogt VM, Post CB, Rossmann MG. Structure and self-association of the Rous sarcoma virus capsid protein. Structure 2000, 8:617-628. 10.1016/S0969-2126(00)00148-9, 10873863.
33. Ako-Adjei D, Johnson MC, Vogt VM. The retroviral capsid domain dictates virion size, morphology, and coassembly of gag into virus-like particles. J Virol 2005, 79:13463-13472. 10.1128/JVI.79.21.13463-13472.2005, 1262573, 16227267.
34. Lanman J, Lam TT, Emmett MR, Marshall AG, Sakalian M, Prevelige PE. Key interactions in HIV-1 maturation identified by hydrogen-deuterium exchange. Nat Struct Mol Biol 2004, 11:676-677. 10.1038/nsmb790, 15208693.
35. Bartonova V, Igonet S, Sticht J, Glass B, Habermann A, Vaney MC, Sehr P, Lewis J, Rey FA, Krausslich HG. Residues in the HIV-1 capsid assembly inhibitor binding site are essential for maintaining the assembly-competent quaternary structure of the capsid protein. J Biol Chem 2008, 283:32024-32033. 10.1074/jbc.M804230200, 18772135.
36. Joshi A, Nagashima K, Freed EO. Mutation of dileucine-like motifs in the human immunodeficiency virus type 1 capsid disrupts virus assembly, gag-gag interactions, gag-membrane binding, and virion maturation. J Virol 2006, 80:7939-7951. 10.1128/JVI.00355-06, 1563813, 16873251.
37. Scholz I, Arvidson B, Huseby D, Barklis E. Virus particle core defects caused by mutations in the human immunodeficiency virus capsid N-terminal domain. J Virol 2005, 79:1470-1479. 10.1128/JVI.79.3.1470-1479.2005, 544128, 15650173.
38. Brun S, Solignat M, Gay B, Bernard E, Chaloin L, Fenard D, Devaux C, Chazal N, Briant L. VSV-G pseudotyping rescues HIV-1 CA mutations that impair core assembly or stability. Retrovirology 2008, 5:57. 10.1186/1742-4690-5-57, 2474847, 18605989.
39. Forshey BM, Shi J, Aiken C. Structural requirements for recognition of the human immunodeficiency virus type 1 core during host restriction in owl monkey cells. J Virol 2005, 79:869-875. 10.1128/JVI.79.2.869-875.2005, 538572, 15613315.
40. Shah VB, Aiken C. In vitro uncoating of HIV-1 cores. J Vis Exp 2011, 57:e3384.
41. Shi J, Zhou J, Shah VB, Aiken C, Whitby K. Small-molecule inhibition of human immunodeficiency virus type 1 infection by virus capsid destabilization. J Virol 2011, 85:542-549. 10.1128/JVI.01406-10, 3014163, 20962083.
42. Diaz-Griffero F, Kar A, Lee M, Stremlau M, Poeschla E, Sodroski J. Comparative requirements for the restriction of retrovirus infection by TRIM5alpha and TRIMCyp. Virology 2007, 369:400-410. 10.1016/j.virol.2007.08.032, 2153441, 17920096.
43. Diaz-Griffero F, Kar A, Perron M, Xiang SH, Javanbakht H, Li X, Sodroski J. Modulation of retroviral restriction and proteasome inhibitor-resistant turnover by changes in the TRIM5alpha B-box 2 domain. J Virol 2007, 81:10362-10378. 10.1128/JVI.00703-07, 2045480, 17626085.
44. Diaz-Griffero F, Vandegraaff N, Li Y, McGee-Estrada K, Stremlau M, Welikala S, Si Z, Engelman A, Sodroski J. Requirements for capsid-binding and an effector function in TRIMCyp-mediated restriction of HIV-1. Virology 2006, 351:404-419. 10.1016/j.virol.2006.03.023, 16650449.
45. Shi J, Aiken C. Saturation of TRIM5 alpha-mediated restriction of HIV-1 infection depends on the stability of the incoming viral capsid. Virology 2006, 350:493-500. 10.1016/j.virol.2006.03.013, 16624363.
46. Leschonsky B, Ludwig C, Bieler K, Wagner R. Capsid stability and replication of human immunodeficiency virus type 1 are influenced critically by charge and size of Gag residue 183. J Gen Virol 2007, 88:207-216. 10.1099/vir.0.81894-0, 17170453.
47. Forshey BM, Aiken C. Disassembly of human immunodeficiency virus type 1 cores in vitro reveals association of Nef with the subviral ribonucleoprotein complex. J Virol 2003, 77:4409-4414. 10.1128/JVI.77.7.4409-4414.2003, 150647, 12634398.
48. Meng X, Zhao G, Yufenyuy E, Ke D, Ning J, Delucia M, Ahn J, Gronenborn AM, Aiken C, Zhang P. Protease Cleavage Leads to Formation of Mature Trimer Interface in HIV-1 Capsid. PLoS Pathog 2012, 8:e1002886. 10.1371/journal.ppat.1002886, 3426514, 22927821.
49. Kelly BN, Kyere S, Kinde I, Tang C, Howard BR, Robinson H, Sundquist WI, Summers MF, Hill CP. Structure of the antiviral assembly inhibitor CAP-1 complex with the HIV-1 CA protein. J Mol Biol 2007, 373:355-366. 10.1016/j.jmb.2007.07.070, 2066180, 17826792.
50. Kortagere S, Madani N, Mankowski MK, Schon A, Zentner I, Swaminathan G, Princiotto A, Anthony K, Oza A, Sierra LJ. Inhibiting Early-Stage Events in HIV-1 Replication by Small-Molecule Targeting of the HIV-1 Capsid. J Virol 2012, 86:8472-8481. 10.1128/JVI.05006-11, 3421734, 22647699.
51. Lemke CT, Titolo S, von Schwedler U, Goudreau N, Mercier JF, Wardrop E, Faucher AM, Coulombe R, Banik SS, Fader L. Distinct effects of two HIV-1 capsid assembly inhibitor families that bind the same site within the N-terminal domain of the viral CA protein. J Virol 2012, 86:6643-6655. 10.1128/JVI.00493-12, 3393593, 22496222.
52. Blair WS, Pickford C, Irving SL, Brown DG, Anderson M, Bazin R, Cao J, Ciaramella G, Isaacson J, Jackson L. HIV capsid is a tractable target for small molecule therapeutic intervention. PLoS Pathog 2010, 6:e1001220. 10.1371/journal.ppat.1001220, 3000358, 21170360.
53. Tang C, Loeliger E, Kinde I, Kyere S, Mayo K, Barklis E, Sun Y, Huang M, Summers MF. Antiviral inhibition of the HIV-1 capsid protein. J Mol Biol 2003, 327:1013-1020. 10.1016/S0022-2836(03)00289-4, 12662926.
54. Chen C, Okayama H. High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol 1987, 7:2745-2752. 367891, 3670292.
55. Yee JK, Friedmann T, Burns JC. Generation of high-titer pseudotyped retroviral vectors with very broad host range. Methods Cell Biol 1994, 43:99-112.
56. Wehrly K, Chesebro B. p24 antigen capture assay for quantification of human immunodeficiency virus using readily available inexpensive reagents. Methods 1997, 12:288-293. 10.1006/meth.1997.0481, 9245608.
57. Aiken C. Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. J Virol 1997, 71:5871-5877. 191842, 9223476.
58. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002, 46:1896-1905. 10.1128/AAC.46.6.1896-1905.2002, 127242, 12019106.